Home Dementias Cancer and Mental Health Re-post : braincancer

Cancer and Mental Health Re-post : braincancer

Hello!

I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly appreciate it. I am re-posting my survey (including my introduction and a description of the survey) a final time for anyone is was interested and didn’t get a chance to participate:

My name is Anthony Cavalier and I am graduate student studying clinical psychology at Immaculata University. As a cancer survivor myself, I know from personal experience how emotionally challenging cancer and its treatment can be. To help make some positive meaning out of my own experience, I’m studying individuals’ attitudes toward, and need for, mental health services during this difficult time. With this in mind, would you please take a few minutes to answer this confidential survey? Your participation will hopefully help to improve the care of future…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Recent Comments